Skip to main content
OpenTrials
Completed

NCT Number: NCT01932814

Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?

The purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury

Completed

Looking for future studies?

Notify Me

Key information

About this study

Severe sepsis and septic shock despite recent advances in surviving sepsis campaign remain encumbered by a high mortality rate close to 30%. One cornerstone of the management of these patients remains the early and appropriate antibiotic administration, , which must be also active at the site of infection. Aminoglycosides are often administered in combination with beta lactams in this context . According to the progress in pharmacokinetic management achieved over the past decade, their safety and efficiency tended to increase but many uncertainties remain. The purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury.

Study design: This is an open retrospective monocentric cohort study including septic critically ill patients from november 2008 to january 2010. To determine the incidence and the specific risk of nephrotoxicity of aminoglycosides, only hospitalized patients without initial acute kidney injury or with rapidly improving kidney function during the three first days will be included.Primary outcome will be the occurrence of acute kidney injury assessed with the RIFLE classification (Risk, Injury, Failure, Loss, and End-stage kidney disease) from day 4 to day 15. Patients receiving aminoglycosides will be compared with a control group, i.e. not receiving them. We estimated hazard ratios (HR) and 95% confidence intervals (CI) with adjusted and propensity score (PS)-matched Cox-proportional hazards models.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 and older
  • Admission to ICU with severe sepsis
  • Hospitalized and without acute kidney injury or with kidney function improved on the third day were included
  • Information provided to the patient or proxy

Exclusion criteria

  • Renal replacement therapy before day 3
  • Patients with renal insufficiency J1 (Day 1 creatinine clearance <56.25 ml/mn/1, 73m2) but severely altered between Day 1 and Day 3 (creatinine clearance Day 1/ Day 3> 1 + Day 3 creatinine clearance <37.5 ml/mn/1, 73m2 ) without renal replacement therapy still necessary before J3
  • Prolonged aminoglycosides therapy

Treatment and study plan

Primary outcomes

  1. The incidence of acute renal injury associated with treatment with aminoglycoside in critically ill septic patients

    Time frame: between day 4 and day 15

Secondary outcomes

  1. Risk factors of acute kidney injury

    Time frame: between day 1and day 3

Other outcomes

  1. Risk factors for ICU mortality

    Time frame: between day 4 and day 15

  2. Pharmacokinetics parameters of aminoglycosides

    Time frame: between day 1 to day 6

    daily dose, peak serum concentration, through level serum concentration

Sponsors and collaborators

Lead sponsor

Université Victor Segalen Bordeaux 2

Other

Registry information

Official study title

Retrospective Analysis of Aminoglycoside-associated Acute Renal Injury in Septic Critically Ill Patients

Acronym: REAMICHOC

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Aug 30, 2013
Registry last updated
Aug 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.